Stroke Prevention in Atrial Fibrillation
The following areas are of research interest:
- Boehringer Ingelheim is interested in studies in patients being treated with Pradaxa that are likely to broaden the information available regarding
- patient subgroups. Examples include ethnicity, age or other groups of clinical interest.
- patient management considerations commonly encountered in patients. Examples include cardioversion, ablation, temporary interruptions of therapy or other concomitant cardiovascular interventions.
- Boehringer Ingelheim is interested in supporting studies in medical conditions where no clinical trials are currently sponsored by Boehringer Ingelheim. This might include, but is not limited to, disorders involving thrombin or those mediated by thrombin activation.
- Boehringer Ingelheim would be interested in studies assessing the utilization of healthcare resources in patients with NVAF.
Prior to submission, please contact the BIPI Medical IIS Office by calling 877-757-7354 for more information and assistance.
After you contact the BIPI Medical IIS Office researchers or physicians must submit a preliminary proposal. In order for BIPI to determine interest in the IIS concept, the following information will be required in the proposal:
- Full title of the study
- Name and contact of principle investigator
- Study rationale
- Study objectives
- Study design
- Statistical methods
- Data Management Plan/System
- Requested Support (Drug, Funding or both)
- Drug Supply Request (BIPI Drug and/or non-BIPI Drug)
- Preliminary Budget (incl. Direct, Indirect Costs and Fees)
Submission of a preliminary Proposal does not imply or guarantee approval. All proposals will be reviewed based on scientific merit and available funding.
